Patents Assigned to Obsidian Therapeutics, Inc.
-
Publication number: 20240131069Abstract: Provided herein are tumor-infiltrating lymphocytes (TILs) engineered to express a membrane-bound interleukin 15 (mbIL15). The mbIL15 TILs can be expanded in vitro using a rapid expansion protocol without the use of exogenous interleukin 2 (IL2) and can be used in adoptive cell therapy without concomitant use of an exogenous cytokine such as IL2. The TIL can be further engineered such that the mbIL15 is operably linked to one or more drug responsive domains (DRDs), polypeptides that can regulate the abundance and/or activity of the IL15 upon binding of the DRD with a ligand. Also provided herein are components for making the modified TILs and methods for making and using the modified TILs.Type: ApplicationFiled: November 2, 2023Publication date: April 25, 2024Applicant: OBSIDIAN THERAPEUTICS, INC.Inventors: Mithun Khattar, Shyamsundar Subramanian, Rachel Burga, Michelle Lynn Ols, Jan ter Meulen, Kyle Pedro, Jeremy Hatem Tchaicha
-
Publication number: 20240108722Abstract: Provided herein are tumor-infiltrating lymphocytes (TILs) engineered to express a membrane-bound interleukin 15 (mbIL15). The mbIL15 TILs can be expanded in vitro using arapid expansion protocol without the use of exogenous interleukin 2 (IL2) and can be used in adoptive cell therapy without concomitant use of an exogenous cytokine such as IL2. The TIL can be further engineered such that the mbIL15 is operably linked to one or more drug responsive domains (DRDs), polypeptides that can regulate the abundance and/or activity of the IL15 upon binding of the DRD with a ligand. Also provided herein are components for making the modified TILs and methods for making and using the modified TILs.Type: ApplicationFiled: January 18, 2022Publication date: April 4, 2024Applicant: OBSIDIAN THERAPEUTICS, INC.Inventors: Kyle Pedro, James Alexander Storer, Jan ter Meulen, Rachel Burga, Mithun Khattar, Michelle Ols, Jeremy Tchaicha, Shyamsundar Subramanian
-
Publication number: 20240075064Abstract: The present disclosure provides compositions and methods for expanding T cells or tumor infiltrating lymphocytes (TILs) in vitro. K562 feeder cells engineered to express a costimulatory molecule (e.g., 41BB ligand (41BBL)) and either interleukin 21 (IL21) or interleukin 7 (IL7) can be used in a rapid expansion protocol (REP) step to expand the T cells or TILs. Thus, provided herein is a culture comprising T-cells or TILs and modified K562 feeder cells. The T cells can be modified to express a chimeric antigen receptor (CAR) or a T cell receptor (TCR) or the TILs can be modified to express membrane-bound IL15 (mbIL15). The T cells or TILs can be expanded in vitro using aREP without the use of exogenous interleukin 2 (IL2), and the expanded cells can be used in adoptive cell therapy for treatment of cancer without concomitant use of an exogenous cytokine such as IL2.Type: ApplicationFiled: January 18, 2022Publication date: March 7, 2024Applicant: OBSIDIAN THERAPEUTICS, INC.Inventors: Kutlu Goksu Elpek, Celeste Richardson, Michelle Lois Fleury, James Alex Storer, Shyamsundar Subramanian, Mithun Khattar
-
Publication number: 20230233608Abstract: The present invention provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.Type: ApplicationFiled: August 16, 2022Publication date: July 27, 2023Applicant: OBSIDIAN THERAPEUTICS, INC.Inventors: Peter Barrett, Michael N. Gladstone, Tariq A. Kassum, Vipin Suri, Dan Jun Li, Dexue Sun, Brian Dolinski
-
Patent number: 11666642Abstract: The present invention relates to compositions and methods for the regulated and controlled expression of proteins. Methods for inducing anti-cancer immune responses in a subject are also provided.Type: GrantFiled: February 1, 2022Date of Patent: June 6, 2023Assignee: OBSIDIAN THERAPEUTICS, INC.Inventors: Vipin Suri, Byron Delabarre, Michael N. Gladstone, Celeste Richardson, Brian Dolinski, Abhishek Kulkarni, Mara Christine Inniss, Dexue Sun, Dan Jun Li, Grace Y. Olinger, Scott Francis Heller
-
Patent number: 11629340Abstract: The present invention is related to compositions and methods for the regulated and controlled expression of proteins.Type: GrantFiled: September 2, 2019Date of Patent: April 18, 2023Assignee: OBSIDIAN THERAPEUTICS, INC.Inventors: Vipin Suri, Dan Jun Li, Dexue Sun, Byron Delabarre, Vijaya Balakrishnan, Brian Dolinski, Mara Christine Inniss, Grace Y. Olinger
-
Publication number: 20230074330Abstract: The present invention relates to compositions and methods for the regulated and controlled expression of proteins. Methods for inducing anti-cancer immune responses in a subject are also provided.Type: ApplicationFiled: February 1, 2022Publication date: March 9, 2023Applicant: Obsidian Therapeutics, Inc.Inventors: Vipin Suri, Byron Delabarre, Michael N. Gladstone, Celeste Richardson, Brian Dolinski, Abhishek Kulkarni, Mara Christine Inniss, Dexue Sun, Dan Jun Li, Grace Y. Olinger, Scott Francis Heller
-
Publication number: 20230056856Abstract: The present disclosure provides compositions and methods related to transcription factor systems. Such systems provide for modular and tunable protein expression driven by regulated transcriptional activity.Type: ApplicationFiled: January 8, 2021Publication date: February 23, 2023Applicant: OBSIDIAN THERAPEUTICS, INC.Inventors: Vipin Suri, Mara Christine Inniss, Samantha Fleury
-
Publication number: 20230026259Abstract: The present disclosure provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities. In particular, the present application is directed to fusion proteins comprising a fragment of human human carbonic anhydrase 2 and a chimeric antigen receptor (CAR). The activity of the destabilizing domain can be regulated by externally administered agents.Type: ApplicationFiled: March 6, 2020Publication date: January 26, 2023Applicant: Obsidian Therapeutics, Inc.Inventors: Vipin SURI, Celeste RICHARDSON, Brian DOLINSKI, Abhishek KULKARNI, Mara Christine Inniss, Dexue SUN, Elizabeth Jane WEISMAN, Grace Y. Olinger, Scott Francis HELLER, Jennifer Leah GORI, Michelle Lynn OLS, Kutlu Goksu ELPEK, Tucker Read EZELL, Michael SCHEBESTA, Michelle Lois FLEURY, Dhruv Kam SETHI
-
Publication number: 20220403001Abstract: The present disclosure relates to tunable biocircuit systems for the development of controlled and/or regulated therapeutic systems. In particular, regulatable biocircuits containing destabilizing domains (DD) derived from mutant human cGMP-specific phosphodiesterase type 5 (PDE5) are disclosed. Especially, the present disclosure provides an effector module. Such effector module may include (a) a stimulus response element (SRE), wherein the SRE is a DD, said DD comprising at least one mutation relative to cGMP-specific 3?,5?-cyclic phosphodiesterase (hPDE5; SEQ ID NO: 1) and (b) at least one payload, which is attached, appended or associated with said SRE. The SRE may be responsive to one or more stimuli.Type: ApplicationFiled: June 12, 2019Publication date: December 22, 2022Applicant: Obsidian Therapeutics, Inc.Inventors: Vipin SURI, Celeste RICHARDSON, Brian DOLINSKI, Abhishek KULKARNI, Mara Christine INNISS, Dexue SUN, Dan Jun LI, Grace Y. OLINGER, Scott Francis HELLER, Jennifer Leah GORI, Byron DELABARRE
-
Patent number: 11446398Abstract: The present invention provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.Type: GrantFiled: April 11, 2017Date of Patent: September 20, 2022Assignee: OBSIDIAN THERAPEUTICS, INC.Inventors: Peter Barrett, Michael N. Gladstone, Tariq A. Kassum, Vipin Suri, Dan Jun Li, Dexue Sun, Brian Dolinski
-
Publication number: 20220213449Abstract: The present invention is related to compositions and methods for the regulated and controlled expression of proteins.Type: ApplicationFiled: December 28, 2021Publication date: July 7, 2022Applicant: Obsidian Therapeutics, Inc.Inventors: Vipin SURI, Dan Jun LI, Dexue SUN, Byron DELABARRE, Vijaya BALAKRISHNAN, Brian DOLINSKI, Mara Christine INNISS, Grace Y. OLINGER
-
Publication number: 20220175781Abstract: The present disclosure provides regulatable biocircuit systems, effector modules and compositions for cancer immunotherapy. Methods for inducing anti-cancer immune responses in a subject are also provided.Type: ApplicationFiled: March 6, 2020Publication date: June 9, 2022Applicant: Obsidian Therapeutics, Inc.Inventors: Michael SCHEBESTA, Michelle Lois FLEURY, Kutlu Goksu ELPEK, Elizabeth Jane WEISMAN, Vipin SURI, Dexue SUN, Dan Jun LI, Steven Mark SHAMAH, Michael Joseph BRISKIN, Celeste RICHARDSON, Tariq A. KASSUM, Michelle Lynn OLS, Brian DOLINSKI, Mara Christine INNISS, Emily BRIDEAU, Jennifer Leah GORI, Dhruv Kam SETHI
-
Publication number: 20220170011Abstract: The present disclosure provides compositions and methods related to regulatable Cas systems. Such systems provide for ligand-dependent, modular and tunable Cas protein expression and activity.Type: ApplicationFiled: December 10, 2021Publication date: June 2, 2022Applicant: OBSIDIAN THERAPEUTICS, INC.Inventors: Mara Christine INNISS, Grace Y. OLINGER, Samantha FLEURY, Jennifer Leah GORI
-
Publication number: 20220056092Abstract: The present disclosure provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.Type: ApplicationFiled: December 11, 2019Publication date: February 24, 2022Applicant: Obsidian Therapeutics, Inc.Inventors: Michelle Lynn OLS, Vipin SURI, Dexue SUN, Dan Jun LI, Dhruv Kam SETHI, Abhishek KULKARNI, Benjamin J. PRIMACK, James STORER
-
Patent number: 11241485Abstract: The present invention relates to compositions and methods for the regulated and controlled expression of proteins. Methods for inducing anti-cancer immune responses in a subject are also provided.Type: GrantFiled: June 12, 2018Date of Patent: February 8, 2022Assignee: OBSIDIAN THERAPEUTICS, INC.Inventors: Vipin Suri, Byron Delabarre, Michael N. Gladstone, Celeste Richardson, Brian Dolinski, Abhishek Kulkarni, Mara Christine Inniss, Dexue Sun, Dan Jun Li, Grace Y. Olinger, Scott Francis Heller
-
Publication number: 20210386788Abstract: The present disclosure is related to compositions and methods for the regulated and controlled expression of proteins.Type: ApplicationFiled: October 23, 2019Publication date: December 16, 2021Applicant: Obsidian Therapeutics, Inc.Inventors: Vipin SURI, Dexue SUN, Michelle Lynn OLS, Scott Francis HELLER, Dan Jun LI, Celeste RICHARDSON, Mara Christine INNISS, Jennifer Leah GORI, Benjamin J. PRIMACK, Abhishek KULKARNI, Brian DOLINSKI, Tucker Read EZELL, Michael SCHEBESTA, James A. STORER, Kutlu Goksu ELPEK
-
Patent number: 11058725Abstract: The present disclosure provides drug responsive domains derived from human carbonic anhydrase 2 that can modulate protein stability for human interleukin 15 (IL15) payloads, as well as compositions and methods of use thereof.Type: GrantFiled: September 10, 2020Date of Patent: July 13, 2021Assignee: Obsidian Therapeutics, Inc.Inventors: Kutlu Goksu Elpek, Dhruv Kam Sethi, Meghan C. Langley, Tucker Read Ezell, Dexue Sun, Jennifer Leah Gori, Geetha Hanna Mylvaganam, Michelle Ols, Michelle Fleury, Celeste Richardson, James A. Storer, Vipin Suri, Shyamsundar Subramanian, Colleen Foley, Molly Reed Perkins, Jeremy Hatem Tchaicha, Scott Francis Heller
-
Publication number: 20210069248Abstract: The present disclosure provides drug responsive domains derived from human carbonic anhydrase 2 that can modulate protein stability for human interleukin 15 (IL15) payloads, as well as compositions and methods of use thereof.Type: ApplicationFiled: September 10, 2020Publication date: March 11, 2021Applicant: Obsidian Therapeutics, Inc.Inventors: Kutlu Goksu ELPEK, Meghan C. LANGLEY, Tucker Read EZELL, Dexue SUN, Jennifer Leah GORI, Geetha Hanna MYLVAGANAM, Michelle OLS, Michelle FLEURY, Celeste RICHARDSON, James A. STORER, Vipin SURI, Shyamsundar SUBRAMANIAN, Colleen FOLEY, Molly Reed PERKINS, Jeremy Hatem TCHAICHA, Scott Francis HELLER